By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mucosis B.V. 

L.J. Zielstraweg 1

Groningen    9713 GX  The Netherlands
Phone: 31-50-3612112 Fax: n/a




Company News
Mucosis B.V. Secures €3.7M From Wellcome Trust To Fund Clinical Trials Of Its Respiratory Syncytial Virus Vaccine In Partnership With Imperial College London 1/20/2016 9:24:21 AM
Mucosis B.V. Presents Data On Intranasal RSV Vaccine SynGEM® At Vaccines 2014 Conference 10/20/2014 7:21:23 AM
Mucosis B.V. Presents Infectious Diseases Vaccines Pipeline Update At Sachs Associates - Bloomberg L.P. 14th Annual Biotech In Europe Forum 9/30/2014 9:44:21 AM
Mucosis B.V. Receives Financial Support From The Dutch Government For Its Syngem® Program 5/22/2014 9:44:29 AM
Mucosis B.V. Announces A Strategic Partnership With Changchun Bcht Biotechnology Of China And Raises Additional Capital 4/15/2014 11:02:25 AM
Mucosis B.V. Signs Research and License Option Agreement With Crucell N.V. (CRXL) 10/8/2012 10:44:12 AM
ExpreS2ion Biotechnologies, Mucosis B.V., and University of Copenhagen Receive Eurostars Grant 9/25/2012 10:31:35 AM
Mucosis B.V. Appoints Thomas Johnston to CEO 9/17/2012 8:20:38 AM
Mucosis B.V. Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans 5/10/2012 9:08:13 AM
Mucosis B.V. Announces Publication of Preclinical Data Demonstrating Superior Protection by Mucosally Administered Mimopath®-Based Influenza Vaccines 5/3/2012 11:05:11 AM